Drug Trial Radar · NCT00112021
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Last checked: Nov 20, 2026Latest source record: Apr 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
May 2005
Primary completion
Nov 2005
Study completion Nov 2005
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 30, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
Conditions
- Obesity
Interventions
pramlintide acetateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To examine the effect of pramlintide on body weight in obese subjectsTime frame: Approximately 16 weeks
- To examine the safety and tolerability of pramlintide in obese subjectsTime frame: Approximately 16 weeks
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Chula Vista, California
Research Site
San Diego, California
Research Site
Walnut Creek, California
Research Site
Miami, Florida
Research Site
Augusta, Georgia
Research Site
Chicago, Illinois
Research Site
Indianapolis, Indiana
Research Site
Overland Park, Kansas
Research Site
Baton Rouge, Louisiana
Research Site
Detroit, Michigan
Research Site
Edina, Minnesota
Research Site
St Louis, Missouri
Research Site
Butte, Montana
Research Site
New York, New York
Research Site
Cincinnati, Ohio
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Austin, Texas
Research Site
San Antonio, Texas
Research Site
Salt Lake City, Utah
Research Site
Olympia, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.